Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Biotechnology
Nuo Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 48.43M shares outstanding
USNuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Leadership
David E. Jorden
Chief Executive Officer, Chief Financial Officer, Secretary & Executive Director
Dean Tozer
Chief Commercial Officer
Martin P. Rosendale
Chief Executive Officer, Director
Peter Clausen
Chief Science Officer
Employees
9
Country
US
Sector
Healthcare
Website
nuot.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Pittman Scott M. | Director | Grant/Award | 4.5K | $6.8K | Oct 6, 2026 |
| Pittman Scott M. | Director | Grant/Award | 458 | $687 | Oct 6, 2026 |
 JORDEN DAVID EMERSON | CEO/CFO | Grant/Award | 8.0K | $8.7K | Aug 28, 2026 |
| JORDEN DAVID EMERSON | CEO/CFO | Grant/Award | 789 | $844.23 | Aug 27, 2026 |
 WINZER C ERIC | Director | Option Exercise | 40.0K | -- | Jun 30, 2026 |
| JORDEN DAVID EMERSON | CEO/CFO | Option Exercise | 162.5K | -- | Jun 30, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
 SHEEDY CHARLES E 10% Owner | 11.6M | 23.9% | FORM 4 |
Pittman Scott M. · may incl. warrants· filed Jun 2026 | 5.6M | 11.6% | 13D |
 JORDEN DAVID EMERSON CEO/CFO, Director | 2.1M | 4.3% | FORM 4 |
 CLAUSEN PETER CSO/COO | 770.1K | 1.6% | FORM 4 |
 WINZER C ERIC Director | 173.1K | 0.4% | FORM 4 |
 Mintz Paul Director | 108.3K | 0.2% | FORM 4 |
Insiders
- Pittman Scott M.Director
- JORDEN DAVID EMERSONCEO/CFO
- WINZER C ERICDirector
- Mintz PaulDirector
- CLAUSEN PETERCSO/COO
- SHEEDY CHARLES E10% Owner
based on 48.43M shares outstanding
US30d Avg
10.54K
60d Avg
7.85K
90d Avg
7.56K